Gapping up
In reaction to earnings/guidance: FNSR +12.5%, ADBE +5.7%, PPHM +4.9%, DTEA +3.8%, KMG +3.3%, (light volume), AGX +0.8%
M&A news: TAOM +6.3% (enters into a definitive agreement and plan of merger with Orient TM Parent Limited; TAOM to be acquired for $$3.767/ADS ), NSC +2.2% (Berkshire Hathaway (BRK.B) considering bid on Norfolk Southern, according to reports -- Berkshire bought Class I Western Rail BNSF in 2010)
Other news: HMY +23.5% (extending this week's move higher), TLGT +8.8% (receives FDA approval of the co's sNDA for CEFOTAN for injection; hopes to launch the product in U.S. in early 2016 ), SUNE +7.3% (SunEdison announced that it has agreed to sell 333 megawatts of wind-power assets to Terra Nova Renewable Partners for $209 million), OTIC +7.3% (announces FDA approval for Otiprio), PBMD +5.8% (announces progress in its collaboration with NEC Corporation and Yamaguchi University in Japan), SGMO +2.2% (presents Phase 2 clinical data from two SB-728-T HIV studies), CSX +2.1% (in symp with NSC), EA +1% (disclosed COO Peter Moore is moving into a new role as Exec VP and Chief Competition Officer, leadingEA's new Competitive Gaming Division)
Analyst comments: CVC +2% (upgraded to Overweight at JP Morgan)